Wilma Wasco, Ph.D.

Associate Professor of Neurology, Harvard Medical School
Associate Geneticist, Massachusetts General Hospital  

Wilma received her PhD from the Albert Einstein College of Medicine and carried out her postdoctoral studies at the Massachusetts Institute of Technology.  Dr. Wasco was part of an international collaborative effort that identified the familial Alzheimer's disease associated presenilin 1 (PS1) and presenilin 2 (PS2) genes. In addition, her laboratory identified genes that encode the two amyloid precursor-like proteins (APLP1 and APLP2) and calsenilin, a calcium binding protein that interacts with the presenilin proteins. Her research has been focused on understanding the biological role that each of these AD-linked proteins plays in the normal, aging and diseased brain. Dr. Wasco is a member of the Genetics and Aging Research Unit and The MassGeneral Institute for Neurodegenerative Disease and she is a Pew Biomedical Scholar. 

Funded Research

Project Description Researchers Funding
Genes to Therapies (G2T) Centralized Research Core Oversight

Wilma Wasco, Ph.D., is responsible for the day-to-day organization of the Genes to Therapies™ (G2T) Centralized Research Core. She meets routinely with Dr. Tanzi as well as the members of the G2T Steering Committee and Meg Smith of Cure Alzheimer’s Fund to outline and discuss progress with timelines and investigations as well as reagent generation and budgets. She will be responsible for determining what reagents are available from investigators or commercial sources while investigators are being recruited.

2014 to 2016